| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S1473-3099(19)30625-5 |
| P698 | PubMed publication ID | 32014117 |
| P2093 | author name string | David M Lewinsohn | |
| Ole F Olesen | |||
| Nick Drager | |||
| Lewis K Schrager | |||
| Johan Vekemens | |||
| P2860 | cites work | Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines | Q24316479 |
| Tuberculosis vaccines and prevention of infection | Q26782022 | ||
| Recent advances in the development of vaccines for tuberculosis | Q26796440 | ||
| CD1 and mycobacterial lipids activate human T cells | Q26863207 | ||
| Nonclassical T cells and their antigens in tuberculosis | Q27007035 | ||
| MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis | Q27016137 | ||
| Quest for correlates of protection against tuberculosis | Q28084282 | ||
| A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data | Q28383049 | ||
| Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors | Q28544684 | ||
| The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling | Q30244104 | ||
| Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers | Q30403003 | ||
| Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity | Q33535876 | ||
| Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. | Q33577145 | ||
| Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models | Q33614952 | ||
| Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. | Q33675370 | ||
| Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study | Q34318665 | ||
| Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries | Q34441930 | ||
| Modeling tuberculosis in nonhuman primates | Q34930509 | ||
| A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection | Q35015787 | ||
| The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents | Q35261953 | ||
| Inherited and acquired immunodeficiencies underlying tuberculosis in childhood | Q35510477 | ||
| Animal models of tuberculosis: Guinea pigs | Q35663870 | ||
| Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis | Q35771345 | ||
| Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection | Q35840672 | ||
| Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? | Q35840685 | ||
| A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates | Q35849628 | ||
| Innate and adaptive immune responses during acute M. tuberculosis infection in adult household contacts in Kampala, Uganda | Q36112137 | ||
| Protection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain | Q36145657 | ||
| Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis | Q36169358 | ||
| B cells and antibodies in the defense against Mycobacterium tuberculosis infection | Q36238031 | ||
| Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis | Q36377090 | ||
| Immunization by a bacterial aerosol | Q36534318 | ||
| M. tuberculosis T Cell Epitope Analysis Reveals Paucity of Antigenic Variation and Identifies Rare Variable TB Antigens | Q36594099 | ||
| MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection | Q37104082 | ||
| Only a subset of phosphoantigen-responsive gamma9delta2 T cells mediate protective tuberculosis immunity | Q37160776 | ||
| Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults | Q37186951 | ||
| Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations | Q37433271 | ||
| New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles | Q37445202 | ||
| Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines | Q37473293 | ||
| Heterologous prime-boost vaccination. | Q37509586 | ||
| Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis | Q38135954 | ||
| Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials | Q38171263 | ||
| Early clearance of Mycobacterium tuberculosis: a new frontier in prevention | Q38206209 | ||
| Antigens for CD4 and CD8 T cells in tuberculosis | Q38213801 | ||
| Aerosol immunisation for TB: matching route of vaccination to route of infection | Q38338183 | ||
| Innovative clinical trial designs to rationalize TB vaccine development | Q38388503 | ||
| The burgeoning family of unconventional T cells | Q38611633 | ||
| Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis. | Q38793308 | ||
| Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial | Q39404079 | ||
| Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques | Q39550322 | ||
| Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. | Q39935921 | ||
| Lipoarabinomannan-Responsive Polycytotoxic T Cells Are Associated with Protection in Human Tuberculosis | Q39993507 | ||
| Ultra low dose aerosol challenge with Mycobacterium tuberculosis leads to divergent outcomes in rhesus and cynomolgus macaques. | Q40826365 | ||
| Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice | Q40916919 | ||
| First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults | Q41148040 | ||
| Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection | Q41335764 | ||
| Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. | Q41411454 | ||
| What Have We Learnt about BCG Vaccination in the Last 20 Years? | Q41684091 | ||
| The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing | Q41836016 | ||
| CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen | Q41939036 | ||
| The duration of protection of school-aged BCG vaccination in England: a population -based case-control study | Q41986442 | ||
| A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin | Q42018546 | ||
| An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection | Q42278752 | ||
| Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination | Q42373425 | ||
| Toward Tuberculosis Vaccine Development: Recommendations for NHP Study Design | Q46296097 | ||
| Boosting with recombinant MVA expressing M. tuberculosis α-crystallin antigen augments the protection imparted by BCG against tuberculosis in guinea pigs | Q47155139 | ||
| Controlled human infections: A report from the controlled human infection models workshop, Leiden University Medical Centre 4-6 May 2016. | Q47210236 | ||
| Tuberculosis vaccines: Opportunities and challenges | Q47552546 | ||
| Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. | Q47553632 | ||
| MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic. | Q47658864 | ||
| Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future? | Q48879396 | ||
| Next-Generation Vaccines Based on Bacille Calmette-Guérin. | Q49829375 | ||
| Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. | Q52623020 | ||
| A multistage tuberculosis vaccine that confers efficient protection before and after exposure. | Q54391413 | ||
| Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. | Q55617820 | ||
| New Promise for Vaccines against Tuberculosis | Q57788338 | ||
| Metabolite changes in blood predict the onset of tuberculosis | Q59791316 | ||
| Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques | Q62737827 | ||
| Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial | Q64080157 | ||
| A Case for Antibodies as Mechanistic Correlates of Immunity in Tuberculosis | Q64260919 | ||
| Rational approach to selection and clinical development of TB vaccine candidates | Q83730558 | ||
| WHO preferred product characteristics for new vaccines against tuberculosis | Q90669089 | ||
| Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | Q90985117 | ||
| Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India | Q91852620 | ||
| P433 | issue | 3 | |
| P921 | main subject | tuberculosis | Q12204 |
| P304 | page(s) | e28-e37 | |
| P577 | publication date | 2020-01-31 | |
| P1433 | published in | Lancet Infectious Diseases | Q15724248 |
| P1476 | title | The status of tuberculosis vaccine development | |
| P478 | volume | 20 |
| Q99592919 | Bacille Calmette Guérin (BCG) and new TB vaccines: Specific, cross-mycobacterial and off-target effects |
| Q97565455 | Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality |
| Q104456936 | The TB vaccine development pathway - An innovative approach to accelerating global TB vaccine development |
Search more.